NuLiv’s AstraGin Ingredient Now GRAS
The company says that AstraGin has been demonstrated in vitro, in vivo, and in humans to significantly promote and improve absorption of amino acids, glucose, and vitamins.
NuLiv Science (Walnut, CA) reports that its signature ingredient AstraGin is now GRAS. AstraGin a combination botanical extract of Panax notoginseng and Astragalus membranaceus roots, intended to improve the human body's absorption of amino acids, glucose, and vitamins.
Both ingredients have reported history of use as tonics, which helped secure the safety approval for AstraGin as a food ingredient. In addition, a 28-day oral toxicity study on rats found no evidence of mortality or clinical health changes following consumption of the equivalent of 100, 300, and 1000 times the suggested daily human dose.
AstraGin is produced in a facility free of gluten, oats, eggs, fish, peanuts, soybeans, milk and other allergenic food ingredients.
GRAS approval was provided by AIBMR Life Sciences (Puyallup, WA).
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
